DK2195013T3 - Terapeutisk anvendelse af en vækstfaktor, METRNL - Google Patents

Terapeutisk anvendelse af en vækstfaktor, METRNL

Info

Publication number
DK2195013T3
DK2195013T3 DK09776234.8T DK09776234T DK2195013T3 DK 2195013 T3 DK2195013 T3 DK 2195013T3 DK 09776234 T DK09776234 T DK 09776234T DK 2195013 T3 DK2195013 T3 DK 2195013T3
Authority
DK
Denmark
Prior art keywords
metrnl
growth factor
therapeutic use
neuroprotective
genes
Prior art date
Application number
DK09776234.8T
Other languages
English (en)
Inventor
Lars Ulrik Wahlberg
Rgensen Jesper Roland Ja
Teit E Johansen
Lone Fjord-Larsen
Nuno Miguel Gomes Andrade
Original Assignee
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsgene As filed Critical Nsgene As
Application granted granted Critical
Publication of DK2195013T3 publication Critical patent/DK2195013T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK09776234.8T 2008-07-24 2009-07-07 Terapeutisk anvendelse af en vækstfaktor, METRNL DK2195013T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8331608P 2008-07-24 2008-07-24
DKPA200801036 2008-07-24
PCT/DK2009/050165 WO2010009732A1 (en) 2008-07-24 2009-07-07 Therapeutic use of a growth factor, metrnl

Publications (1)

Publication Number Publication Date
DK2195013T3 true DK2195013T3 (da) 2012-02-06

Family

ID=41314584

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09776234.8T DK2195013T3 (da) 2008-07-24 2009-07-07 Terapeutisk anvendelse af en vækstfaktor, METRNL

Country Status (10)

Country Link
US (4) US8334264B2 (da)
EP (1) EP2195013B1 (da)
JP (1) JP5616888B2 (da)
CN (1) CN102164611B (da)
AT (1) ATE531383T1 (da)
AU (1) AU2009273600B2 (da)
CA (1) CA2730710C (da)
DK (1) DK2195013T3 (da)
HK (1) HK1145070A1 (da)
WO (1) WO2010009732A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164611B (zh) 2008-07-24 2015-01-07 Ns基因公司 生长因子metrnl的治疗用途
KR101886029B1 (ko) * 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
EP2753347B1 (en) * 2011-09-05 2016-08-03 NsGene A/S Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
US10717992B2 (en) 2013-01-25 2020-07-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
WO2014183207A1 (en) * 2013-05-17 2014-11-20 Exerkine Corporation Therapeutic method of treating metabolic syndrome
CN103536903B (zh) * 2013-10-29 2015-04-15 中国人民解放军第二军医大学 Metrnl蛋白在制备降血脂药物方面的应用
CN103536904B (zh) * 2013-10-29 2015-02-18 中国人民解放军第二军医大学 Metrnl蛋白在制备降血糖药物方面的应用
WO2015062167A1 (zh) * 2013-10-29 2015-05-07 中国人民解放军第二军医大学 Metrnl蛋白在制备降血脂降血糖药物中的应用
US11434501B2 (en) 2014-08-28 2022-09-06 Board Of Trustees Of Michigan State University Sprr1A as a genetic target for treating neurodegenerative diseases
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US9687483B2 (en) * 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
CN104977415A (zh) * 2015-03-09 2015-10-14 中国人民解放军第二军医大学 Metrnl蛋白作为炎症性肠病诊断血清标志物的应用及其试剂盒
CN104808004B (zh) * 2015-05-06 2017-03-01 中国人民解放军第二军医大学 Metrnl蛋白作为结肠癌诊断标志物的应用及试剂盒
KR101586054B1 (ko) * 2015-11-20 2016-01-21 고려대학교 산학협력단 메테오린-유사체 (meteorin-like)를 포함하는 유방암의 예방 또는 치료용 조성물
CN107088223B (zh) * 2016-02-17 2020-07-07 中国人民解放军第二军医大学 Metrnl蛋白或基因在治疗内皮功能受损中的应用
DE102016204700A1 (de) 2016-03-22 2017-09-28 Universität Rostock Rekombinante Herstellung von Subfatin
CN107537025B (zh) * 2016-06-23 2020-01-10 上海风劲生物医药科技有限公司 Metrnl蛋白或基因在调节抗菌肽表达中的应用
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US20180250287A1 (en) * 2017-03-06 2018-09-06 Tactus Therapeutics, Inc. Abuse deterrent opioid formulations
WO2019014322A1 (en) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
WO2019081673A1 (en) * 2017-10-25 2019-05-02 Nouscom Ag LINE OF EUKARYOTIC CELLS
CN110227146A (zh) * 2018-03-06 2019-09-13 上海风劲生物医药科技有限公司 Metrnl蛋白或基因在防治认知障碍方面的应用
WO2020056056A1 (en) * 2018-09-12 2020-03-19 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
ATE226250T1 (de) * 1992-04-30 2002-11-15 Innogenetics Nv Polypeptide und peptide dafür kodierende nukleinsaüre und ihre verwendung im zusammenhang mit tumortherapie, entzündung oder immunology
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
AU7452300A (en) 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
CA2390415A1 (en) 1999-11-30 2001-06-07 Innogenetics N.V. New uses of suppressive macrophage activation factors
WO2001055321A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2395676A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
AU2001255668A1 (en) 2000-05-02 2001-11-12 Human Genome Sciences, Inc. 29 human secreted proteins
AU2002364968A1 (en) 2001-12-21 2003-09-02 Diadexus, Inc. Compositions and methods relating to hepatic specific genes and proteins
WO2004035732A2 (en) 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050208500A1 (en) 2003-03-04 2005-09-22 Erlander Mark G Signatures of ER status in breast cancer
EP2289911A3 (en) * 2004-03-30 2011-03-30 NsGene A/S Therapeutic use of a growth factor, NsG33
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
CN102164611B (zh) * 2008-07-24 2015-01-07 Ns基因公司 生长因子metrnl的治疗用途
KR101886029B1 (ko) 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
EP2753347B1 (en) 2011-09-05 2016-08-03 NsGene A/S Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain

Also Published As

Publication number Publication date
EP2195013A1 (en) 2010-06-16
CA2730710C (en) 2021-06-08
US20170333526A1 (en) 2017-11-23
US20130267464A1 (en) 2013-10-10
HK1145070A1 (en) 2011-04-01
ATE531383T1 (de) 2011-11-15
AU2009273600B2 (en) 2013-04-18
US20160045564A1 (en) 2016-02-18
CA2730710A1 (en) 2010-01-28
US9675669B2 (en) 2017-06-13
US20110112035A1 (en) 2011-05-12
US8334264B2 (en) 2012-12-18
CN102164611A (zh) 2011-08-24
US10034918B2 (en) 2018-07-31
WO2010009732A1 (en) 2010-01-28
JP2011528558A (ja) 2011-11-24
CN102164611B (zh) 2015-01-07
US9068015B2 (en) 2015-06-30
AU2009273600A1 (en) 2010-01-28
EP2195013B1 (en) 2011-11-02
JP5616888B2 (ja) 2014-10-29

Similar Documents

Publication Publication Date Title
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
MX2009012623A (es) Moduladores de cinasa heterociclicos.
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
TW200833692A (en) Triazolopyridazine protein kinase modulators
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
MX2009007406A (es) Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
MY159551A (en) High affinity human antibodies to human protease-activated receptor-2
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA202091999A2 (ru) Применение ингибиторов dpp iv
MX2009011025A (es) Compuestos con actividad anticancer.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
DK1745069T3 (da) Terapeutisk anvendelse af vækstfaktoren NSG33
WO2008097861A3 (en) MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
MX2009012969A (es) Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.
EP3818991A3 (en) Compositions and methods for treating diseases
EA201070195A1 (ru) ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ